Development of a Maternal Vaccine forGroup B Streptococcus (GBS)
Karen Slobod MD5 Nov 2013
Agenda
Epidemiologyand epidemiology
NVD trivalent maternal vaccine
Clinical Development Approach
2 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
H1N11
• Pregnant women = 13% of all H1N1 deaths
• Most childhood deaths < 6 mo of age
Influenza and Tdap routinely recommended in pregnancy2: Seasonal influenza vaccination recommended for all pregnant
women UK uptake = 40.3%
Tdap: “Immunisation could be offered at one of the routine antenatal visits following the routine week 20 anomaly scan” UK uptake ≈ 50%
GBS: Prime candidate for prevention by maternal vaccination• 95% of all ‘early’ infection occurs within 48 hrs, before infant vaccine can
take effect1 Zuccotti GV, et al. JAMA 304:2360-612 JCVI Notes
Maternal Immunization: rationalePrevention of the earliest infections
3 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Group B streptococcus (GBS)Leading cause of neonatal sepsis and meningitis globally
Transmission:• Mother to infant:
20-25% women are colonized (global) ..................................................200/1000
↓ ↓50% of babies born to these mothers are
colonized .............................100/1000 ↓ ↓2% become
infected...............................................................................2/1000
• 95% of ‘early’ onset disease (EOD: 0-6 days) occurs within 48 hrs
• Median age of ‘late’ onset disease (LOD: 7-89 days) is 37 days (3rd quartile is 53 days)
• Maternal vaccination needed to prevent such early infection
4 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
GBS Neonatal DiseaseUnmet medical need
1 Lamagni TL, et al. CID 57:682; 2013.2 Edmond K, et al. Lancet 20113 Weisner 2004; Clin Infect Dis 2004; 38: 1203-08
Leading cause of neonatal sepsis and meningitis in the first 3 months of life
UK incidence: EOD + LOD = 0.7 cases/1000 live births (~500 cases/yr)1
Case fatality rate (UK): 8-9%2-3
5 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
GBS: Important cause of bacterial meningitisUnmet medical need
1 Phares CR, et al. JAMA 2008..2 Colbourn 2007 Health Technologies Assess (11) No 29; 20073 Libster R, et al. Pediatrics, 2012.
4 NEJM 357:918-25, 2007
Meningitis occurs among 7% of EOD and 27% LOD1
Case fatality rate among meningitis cases: up to 23% in preterm infants and 12% in term infants2.
Long-term neurologic sequelae/disability in almost half of GBS meningitis cases3,4
6 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
IAP = Intravenous ampicillin q4h during labor for women at risk. Risk determined:
• Universal screening: All pregnant women are screened at ~35-37 wks gestation → all colonized women receive IAP (e.g. USA)
• Clinical factors: previous infant with GBS disease, prematurity, PROM, fever (e.g. UK)
Prevention: No vaccine yet licensedIntrapartum antibiotic prophylaxis (IAP) only prevention
7 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Cas
es /
1,00
0 liv
e b
irth
sGBS: Universal screening and IAP (US) Reduced but not eradicated disease
Incidence of invasive GBS disease among infants (recommendations issued 1993)
8 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
GBS: Risk-based IAP (UK)Little change with risk-based IAP
Source: Lamagni, T et al. CID, 2013
RCOG guidelines for GBS implemented
In the UK, IAP-eligible women are identified via risk factors; no evident decrease in cases since the recommendations were issued in 2003
Incidence of EOD and LOD in the England and Wales and N. Ireland between 2003-2011
9 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
GBS: Lead cause pediatric bacterial meningitis (US)Causes >85% meningitis in infants <2mo (US)
1. Thigpen MC, et al. Bacterial meningitis in the United States 1998-2007. NEJM 364:2016, 2011.
10 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Ab against CPS protects against neonatal infection:
1. GBS capsular polysaccharide conjugate (CPS-CRM197) vaccines protect in GBS neonatal pup challenge model1
2. Passive transfer of anti-CPS Ab protects newborn mice2
3. Low levels of maternal anti-CPS Ab correlate with neonatal disease susceptibility3
4. Higher levels of maternal anti-CPS Ab correlate with reduced risk of neonatal disease4,5
GBS: Maternal vaccine can be protectiveLong-standing data supports protection of maternal anti-CPS Ab
1Vaccine 2001;19:2118-21262JID 1992;166:635-6393NEJM 1976; 294:753-7564JID 2001;184:1022-10285JID 2004;190:928-934
11 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Females immunized(0 and 21 days)
+
Mating
(day 21)
GBS challenge of pups at 24-48 hrs age
(intraperitoneal, 90% LD)
Measure2 day survival
Key data: GBS CPS-specific Ab protectsPups born to vaccinated dams survive lethal challenge
Anti-CPS Ab protects - NVD glycoconjugates protect.
% Survival (Alive/Treated) Vaccineserotype Challenge strain (type) CRM-conjugate PBS
Ia 090 (Ia) Ib 7357B (Ib) III COH1 (III)
86% (54/63) 73% (71/97) 93% (95/102)
0% (0/59) 0% (0/38) 2% (1/48)
12 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Trivalent glycoconjugate vaccineNovartis GBS vaccine
Vaccine: CRM197 conjugated capsular polysaccharide representing three serotypes (at 1:1:1 ratio):
» Ia» Ib» III
Trivalent coverage ≈ 79% globally
Bacterial capsular polysaccharide
Glycoproteinconjugate
CRM protein
13 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
0
20
40
60
80
100
120
0 20 28 32 40
Gestational Age
% m
ater
nal
Ab
in
co
rd b
loo
d
GBS: Maternal vaccination allows infant protectionPlacental transfer increases markedly >32 wks
3-6 mo
Decay of passively
transferred AbPassive Ab transfer occurs largely in third trimester
14 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Novartis: GBS vaccine development
Phase I
Formulation
Serotype Ib & III)
Monovalent: Serotype Ia
Trivalent PG US
Phase II Trivalent HIV+/- PG
Phase Ib/II Trivalent PG
Trivalent (Ia, Ib & III), NPG
Trivalent PG (functional Ab)
Trivalent: Phase I
Non-pregnantPregnantTrial completeRecruiting completeFSFV in next 9 mo
NPG:PG:
15 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
No added benefit from aluminum hydroxide, 2 injections or 20 vs 5 ugStudy 1: GBS Trivalent Vaccine in Non-pregnant women
Cu
mu
lativ
e P
erc
en
tag
e
GBS ELISA Concentrations (mg/mL)
16 | ESPID | Karen Slobod | 30 May 2013 | GBS Vaccine | Confidential
Adjuvant No Alum AlumPlacebo (saline)
Injection # 1 2 1 2 2
Dose (each GC) 5 µg 20 µg 5 µg 20 µg 5 µg 20 µg 5 µg 20 µg 0 µg
n 40 38 40 40 40 39 40 38 18
Reverse Cumulative Ab Distribution: Serotype Ia at day 61
GBS Vx dosage1
(Ia/Ib/III GC)Study subjects (n)
0.5/0.5/0.5 µg 80
2.5/2.5/2.5 µg 80
5/5/5 µg 80
Placebo (saline) 80
Subjects: Healthy, pregnant women between 28-35 wks gestation (18-40 yrs) Study site: South Africa
1 Formulated without adjuvant; administered as a single injection
Delivery
Objective: Select dosage in pregnant womenStudy 2: Phase Ib/II study in pregnant women
17 | ESPID | Karen Slobod | 30 May 2013 | GBS Vaccine | Confidential
Cu
mu
lativ
e P
erc
en
tag
e
GBS Ia ELISA Delivery
GBS ELISA Concentrations (mg/mL)
5 mg ▲ - _____ (N = 75)
2.5 mg * - --------- (N = 77)
0.5 mg ● - ______ (N = 77)Placebo ■ - _ _ _ _ (N = 76)
All subjectsStudy 2: Ph II Dose-ranging in pregnant women
Reverse Cumulative Distribution at delivery: Serotype Ia
18 | ESPID | Karen Slobod | 30 May 2013 | GBS Vaccine | Confidential
Ph II Dose-ranging in PG: Serotype IaSubjects < limit of detection at baseline
5 mg ▲ - _____ (N = 43)
2.5 mg * - --------- (N = 42)
0.5 mg ● - ______ (N = 31)Placebo ■ - _ _ _ _ (N = 39)
Cu
mu
lativ
e P
erc
en
tag
e
GBS Ia ELISADelivery
GBS ELISA Concentrations (mg/mL)
5 ug dosage superior
19 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Reverse Cumulative Distribution at delivery: Serotype Ia
Novartis GBS VaccineImmunogenic and well-tolerated in NPG and PG women
5/5/5 µg
Single injection administered between 28-35 weeks gestation
No adjuvant (no preservatives)
20 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
GBS Maternal Vaccine: Phase III StudyEnroll and vaccinate mothers; follow mothers and infants
Phase III study:• Size: >10,000 mothers → >10,000 infants
• Eligibility: women between 28-35 wks gestation
• End-points: Mother/infant safety; vaccine immunogenictiy (efficacy); infant response to CRM-containing vaccines
EnrollMothers
Immunize Delivery
Infant(>10,000)
Mother(>10,000)
21 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
GBS Maternal Vaccine DevelopmentNext Steps
Complete Ph II dose-ranging studies - placental transfer
- functional Ab
Ph III maternal/infant study start• Planned start Q1 2015
• Global study enrolling >10k pregnant women in EU/US/global
Ongoing advocacy for role of maternal vaccination in prevention of neonatal disease
22 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only
Contributors
ResearchJohn TelfordPaolo CostantinoDomenico MaioneFrancesco BertiEmanuela PallaElena MoriBarbara BaudnerMikkel NissumMaria Rosaria RomanoMarzia Giuliani
TechOps/TDStefano RicciStefania BertiStefania FerrariStefania PezzottiAntonella Damarini
Fabiana BaldoniFriedhelm HellingGabriella RolliMario ContorniLorenzo TarliConcetta CicalaMassimo PaciniHans Joachim MaiManfred BoeseMelanie MucheFrancesca TittaFrancesco NorelliFrederica SpongaValeria Carinci
Development• Pietro Forte• Irving Boudville• Richard de Rooij• Geert Prins• Anke Hilbert• Annette Karsten• Rachid Marhaba
Silvia BenocciSue FeketeLisa BedellAllen IzuKatherine LanierWayne WooAlessandra SchiavoneJonathan GoNarcisa Cuceanu Ana Vila RealAldo SchepersRenate Enzinga
GBS Global Program Team
Stephen ChoBrian CooperMarianne CunningtonLaura DeschenesPeter Dull Guido GrandiDominika KovacsMartha LeibbrandtImma Margarit Y RosMariska Mulder
23 | MRF | K Slobod | 5 Nov 2013 | Maternal GBS Vx | Business Use Only